Literature DB >> 21390517

Interstitial pneumonitis induced by pegylated liposomal doxorubicin in a patient with recurrent ovarian cancer.

Kanako Inaba1, Takahide Arimoto, Mari Hoya, Kei Kawana, Shunsuke Nakagawa, Shiro Kozuma, Yuji Taketani.   

Abstract

Interstitial pneumonitis after treatment with pegylated liposomal doxorubicin (PLD) has been rarely reported. We describe herein a case of interstitial pneumonitis in a 49-year-old woman with relapsed ovarian carcinoma treated with PLD. Twenty-five days after the second administration of PLD, she presented with fever and dry cough, and chest CT scans revealed bilateral interstitial infiltrates and ground-glass opacities. She was diagnosed to have interstitial pneumonitis induced by PLD. Steroid therapy improved her symptoms.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21390517     DOI： 10.1007/s12032-011-9893-0

Source DB:  PubMed          Journal:  Med Oncol        ISSN： 1357-0560            Impact factor:   3.064


  10 in total

1.  Interstitial pneumonitis after treatment with bevacizumab and pegylated liposomal doxorubicin in a patient with metastatic breast cancer.

Authors:  Jens Huober; Otto Schoch; Arnoud Templeton; Christian Spirig; Beat Thürlimann
Journal:  Chemotherapy       Date:  2010-02-08       Impact factor: 2.544

2.  Increased levels of KL-6 and subsequent mortality in patients with interstitial lung diseases.

Authors:  H Satoh; K Kurishima; H Ishikawa; M Ohtsuka
Journal:  J Intern Med       Date:  2006-11       Impact factor: 8.989

3.  Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan.

Authors:  A N Gordon; J T Fleagle; D Guthrie; D E Parkin; M E Gore; A J Lacave
Journal:  J Clin Oncol       Date:  2001-07-15       Impact factor: 44.544

Review 4.  Role of pegylated liposomal doxorubicin in ovarian cancer.

Authors:  J Tate Thigpen; Carol A Aghajanian; David S Alberts; Susana M Campos; Alan N Gordon; Maurie Markman; D Scott McMeekin; Bradley J Monk; Peter G Rose
Journal:  Gynecol Oncol       Date:  2005-01       Impact factor: 5.482

5.  Leflunomide induced acute interstitial pneumonia.

Authors:  Michio Takeishi; Yuji Akiyama; Haruhiko Akiba; Daisuke Adachi; Motoharu Hirano; Toshihide Mimura
Journal:  J Rheumatol       Date:  2005-06       Impact factor: 4.666

6.  Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer.

Authors:  Alan N Gordon; Margaret Tonda; Steven Sun; Wayne Rackoff
Journal:  Gynecol Oncol       Date:  2004-10       Impact factor: 5.482

7.  Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer.

Authors:  Gabriella Ferrandina; Manuela Ludovisi; Domenica Lorusso; Sandro Pignata; Enrico Breda; Antonella Savarese; Pietro Del Medico; Laura Scaltriti; Dionyssios Katsaros; Domenico Priolo; Giovanni Scambia
Journal:  J Clin Oncol       Date:  2008-02-20       Impact factor: 44.544

8.  FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets.

Authors:  Martin H Cohen; Grant A Williams; Rajeshwari Sridhara; Gang Chen; Richard Pazdur
Journal:  Oncologist       Date:  2003

9.  Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies.

Authors:  B Uziely; S Jeffers; R Isacson; K Kutsch; D Wei-Tsao; Z Yehoshua; E Libson; F M Muggia; A Gabizon
Journal:  J Clin Oncol       Date:  1995-07       Impact factor: 44.544

10.  Rituximab-CHOP induced interstitial pneumonitis in patients with disseminated extranodal marginal zone B cell lymphoma.

Authors:  Kwang Min Kim; Ho-Cheol Kim; Kyung-Nyeo Jeon; Hoon-Gu Kim; Jung Hun Kang; Jong Ryeal Hahm; Gyeong-Won Lee
Journal:  Yonsei Med J       Date:  2008-02-29       Impact factor: 2.759
  10 in total
  5 in total

1.  Fatal pneumonitis after treatment with pegylated liposomal doxorubicin in a patient with metastatic breast cancer in complete remission.

Authors:  Michael Mark; Beat Thürlimann
Journal:  Med Oncol       Date:  2012-09       Impact factor: 3.064

2.  Inhalable PEGylated Phospholipid Nanocarriers and PEGylated Therapeutics for Respiratory Delivery as Aerosolized Colloidal Dispersions and Dry Powder Inhalers.

Authors:  Priya Muralidharan; Evan Mallory; Monica Malapit; Don Hayes; Heidi M Mansour
Journal:  Pharmaceutics       Date:  2014-06-20       Impact factor: 6.321

3.  Pulmonary Fibrosis after Pegylated Liposomal Doxorubicin in Elderly Patient with Cutaneous Angiosarcoma.

Authors:  Marco Mazzotta; Raffaele Giusti; Daniela Iacono; Salvatore Lauro; Paolo Marchetti
Journal:  Case Rep Oncol Med       Date:  2016-01-20

4.  Epithelial cell senescence induces pulmonary fibrosis through Nanog-mediated fibroblast activation.

Authors:  Xiang Chen; Hongyang Xu; Jiwei Hou; Hui Wang; Yi Zheng; Hui Li; Hourong Cai; Xiaodong Han; Jinghong Dai
Journal:  Aging (Albany NY)       Date:  2019-12-31       Impact factor: 5.682

5.  Selective interstitial doxorubicin for recurrent glioblastoma.

Authors:  Valerii Matcovschii; Dan Lisii; Valentin Gudumac; Stanislav Dorosenco
Journal:  Clin Case Rep       Date:  2019-11-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.